First participant enrolled in multi-center prospective, observational, case control study with target enrollment of >5,000
Initial institutions include City of Hope and Cleveland Clinic
TORONTO, May 25, 2022. Adela, Inc., focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test, has enrolled the first participant in a multi-center study supporting the development and validation of its genome-wide methylome enrichment platform for the early detection of cancer. Adela's platform efficiently captures genome-wide methylome information from small quantities of cell-free DNA and applies machine learning to detect and classify underlying disease.
The CAMPERR study is a prospective, observational, case-control study enrolling over 5,000 participants at multiple centers across the United States. The study will enroll participants with types of cancer that represent >90% of cancer incidence and >85% of cancer mortality1, as well as age- and gender-matched controls without a diagnosis of cancer. The study will support the development and validation of Adela’s multi-cancer early detection (MCED) test. The study will also include longitudinal sampling on a subset of participants to support development of Adela’s platform for measuring minimal residual disease (MRD) and detecting recurrence.
“We are excited to collaborate with leading institutions and investigators to conduct this high caliber study supporting the development of a best-in-class MCED product,” said Anne-Renee Hartman, Chief Medical Officer at Adela. “The CAMPERR Study has been rigorously designed to ensure that Adela’s MCED test will be generalizable at population-scale and clinicians can have high confidence in the test performance characteristics. In addition to incorporating age and gender-matching for controls, the study will include broad geographic representation and enroll participants with co-morbid conditions.”
The CAMPERR Study is currently enrolling participants at City of Hope, a cancer research and treatment organization, and Cleveland Clinic. Additional institutions will be added.
“I am encouraged by initial data suggesting that Adela’s platform has the potential for robust detection of Stage I and II disease across many cancer types, including such lethal cancers as kidney, pancreatic, lung, and primary brain tumors” said Dr. Greg Idos, Principal Investigator for the CAMPERR Study at City of Hope. “I look forward to further evaluating the potential of the platform for the early detection of multiple cancer types through the CAMPERR Study.”
Adela has also collaborated with University Health Network’s Princess Margaret Cancer Centre to explore the ability of Adela’s platform to detect multiple types of early-stage cancers in several patient cohorts.
Adela is developing its technology initially for use across the cancer continuum for detection, diagnosis, and management, and will expand the technology in the future to other conditions beyond cancer. Adela’s technology has the potential for detection of early-stage cancer with unprecedented sensitivity and classification of the underlying disease, including tissue of origin and histologic subtype. Increased detection of cancers in early stages when they can be more effectively treated can lead to better outcomes.
